Abstract A ruthenium based catalytic system ([Ru(p-cymene)Cl2]2/XantPhos with substoichiometric Cs2CO3) has been established to effectively achieve the first direct amination cyclization of 1,2,4-butanetriol with primary aromatic amines. The product of this sustainable hydrogen autotransfer process is valuable N-aryl-3-pyrrolidinol.
to suppress the degradation of sugars and obtain high yields of deoxy C6 products. With this knowledge, the improvement of a standard commercial Cu-RANEY® catalyst under optimized reaction conditions was shown. In contrast to alumina-supported Cu, the Cu–Al alloy in a RANEY®-type catalyst shows selective –C–O– bond cleavage properties while maintaining the C6 carbon chain. These new insights into the
Enhancement of cyclic ether formation from polyalcohol compounds in high temperature liquid water by high pressure carbon dioxide
作者:Aritomo Yamaguchi、Norihito Hiyoshi、Osamu Sato、Kyoko K. Bando、Masayuki Shirai
DOI:10.1039/b812318g
日期:——
Cyclic ethers were produced by a dehydration reaction of polyalcohol compounds in high temperature liquid water, which was accelerated by the presence of carbon dioxide dissolved in the water. 3-hydroxytetrahydrofuran was produced by the dehydration of 1,2,4-butanetriol. Both tetrahydrofurfuryl alcohol and 3-hydroxytetrahydropyran were produced by the dehydration of 1,2,5-pentanetriol. Five-membered
[EN] IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS<br/>[FR] LIPIDES AMINÉS AMÉLIORÉS ET PROCÉDÉS D'ADMINISTRATION D'ACIDES NUCLÉIQUES
申请人:TEKMIRA PHARMACEUTICALS CORP
公开号:WO2010042877A1
公开(公告)日:2010-04-15
The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule
preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a panel of 22 protein kinases and in cells. Consistently, 6ha inhibited tumor cell growth in the NCI 60 cell line panel and induced apoptosis. The results indicate that the 5′-position provides limited space for chemicalmodifications and identify 6ha as a potent water-soluble indirubin-based IGF-1R inhibitor.